Ragweed allergy has long been recognized as a major public health problem, with various incidence and prevalence rates in different geographic areas. Allergic rhinoconjunctivitis and asthma are the most common manifestations of allergic sensitization, although skin symptoms may occur. Ten to 26% of the USA population is estimated to be affected (Arbes et al, JACI 2005), which generates diagnosis, treatment and medication costs of approximately $21 billion per year (Ziska et al, PNAS 2011). In Europe, the sensitization frequency varies tremendously between countries (Burbach et al, Allergy 2009), from 2.4% in the Western parts of Europe and up to 50% in the Eastern parts of Europe, with an overall rise in prevalence (Tosi A et al, Swiss Med Wkly 2011). The estimated costs for diagnosis and treatment of ragweed allergy in the EU range up to € 714 million per year. According to WAO, ragweed impact on health of people living in Asia is less significant than in Europe and North America. In Japan, the most frequent cause of allergic rhinoconjunctivitis (for 10% of the population) is the Japanese cedar pollen, followed at a distance by cypress, grasses, ragweed, and mugwort.